【摘要】 背景与目的 分子靶向治疗是肺癌个体化治疗的方向，目前已有学者建立靶向治疗预测模型，为 临床个体化治疗提供更多的指导。本研究探讨血清肺表面活性物质相关蛋白（pulmonary surfactant-associated protein D, SP-D）、转化生长因子-α（transforming growthfactor α, TGF-α）、基质金属蛋白-9（matrix metalloproteinase 9, MMP-9）、组织多肽特异性抗原（tissue polypeptide specific antigen, TPS）、肺腺癌相关抗原（Krebs von den Lungen-6, KL-6）与晚期复治非小细胞肺癌（non-small cell lung cancer, NSCLC）治疗疗效及生存的关系，并构建生存预测模 型。方法 采用酶联免疫吸附法（enzyme-linked immuno sorbent assay, ELISA）检测114例晚期复治NSCLC患者治疗前 forming growth factor α (TGF-α), matrix metalloproteinase 9 (MMP-9), tissue polypeptide specific antigen (TPS), and Krebs von den Lungen-6 (KL-6) and response as well as survival in the patients with recurrent non-small cell lung cancer, which Erlotinib was as second line treatment after failure to chemotherapy. This study also established a predictive prognostic model.
Methods Serum levels of SP-D, TGF-α, MMP-9, TPS, and KL-6 in 114 patients before erlotinib treatment were detected by ELISA method. Combined with clinical factors, these levels were used to investigate the relationship with efficacy in erlotinib treatment and construct a predicted prognostic model by Kaplan-Meier curve and Cox proportional hazard model multivariate analysis. Results The objective response rate (ORR) and disease control rate (DCR) in the 114 patients, were 22.8% (26/114) and 72.8% (83/114), to Erlotinib treatment respectively. The median progression-free survival (PFS) and one year survival rate with Erlotinib treatment were 5.13 months and 69.3%, respectively. Patients in the SP-D>110 ng/mL group exhibited more ORR (33.3% vs 13.3%, P=0.011) and DCR (83.3% vs 63.3%, P=0.017) than those in the ≤110 ng/mL group. Patients in the MMP-9≤535 ng/mL group showed more DCR (83.9%) than those in the >535 ng/mL group (62.1%) (P=0.009). Patients in the TPS<80 U/L group showed more DCR (82.4%) than those in the ≥80 U/L group (55.0%) (P=0.002). The SP-D>110 ng/ mL (5.95 months vs 3.25 months, P=0.009), MMP-9≤535 ng/mL (5.83 months vs 3.47 months, P=0.046), KL-6<500 U/mL (6.03 months vs 3.40 months, P=0.040), and TPS<80 U/L (6.15 months vs 2.42 months, P=0.014) groups showed better PFS. Multivariate analysis showed that current or ever-smoker, wild style of EGFR status, progression after prior chemotherapy, absence of skin rash, elevated serum LDH level, and TPS≥80 U/L were independent adverse prognostic factors for PFS. These six factors were used in the prognostic model. Patients were categorized into four prognosis risk groups based on the prog- www.lungca.org 
